FERMENTA BIOTECH LTD.

Manufactures pharmaceutical active ingredients (APIs), intermediates and nutritional premixes, with vitamin D3 driving 87% of turnover. Operations are organised around three core verticals disclosed in the FY26 investor presentation: a Human Nutrition line built on vitamin D3 (Rs 293 crore in FY26, up 28% year-on-year), an Animal Nutrition business (Rs 109 crore, up 32%), and a smaller Green Chemistry unit whose sales more than doubled to Rs 16 crore, alongside a residual Property segment. The company exports 58% of output to around 60 countries and serves more than 400 customers. Manufacturing quality systems are certified to EU-GMP, USFDA, WHO-GMP and ISO standards. In July 2026 it received FSSAI approval for its plant-source vitamin D3 (VITADEE Green) for use in Indian fortified foods and supplements. The cost structure is led by materials (28.3% of revenue) and other operating expenses (28.8%), with employee costs at 15.7% and depreciation at 4.1%; capex ran at 5.8% of revenue. FY26 consolidated revenue was Rs 548 crore and standalone revenue Rs 525 crore, with EBITDA margin around 22-25%. AR · MarketPing reader · 2026-08-02

Revenue streams, as the annual report describes them. Human Nutrition (Vitamin D3), Animal Nutrition, Green Chemistry, Property. Manufacturing-led pharma and biotech with concentrated single-product exposure to vitamin D3

Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)